Developing a Correct System to Evaluate the Accuracy of Gleason Score in Prostate Cancer of Chinese Population

A study was conducted to develop a new correct system to improve the overall rate of Gleason sum concordance between biopsy and final pathology.

A total of 592 consecutive patients who had undergone transrectal ultrasound-guided prostate biopsy and radical prostatectomy were evaluated during the first stage.

Age, PSA, PSA density (PSAD), biopsy cores, positive cores, prostate volume, positive core rate (PCR), core volume rate (CVR) and digital rectal examination findings were considered predictive factors. A multiple logistic regression analysis involving a backward elimination selection procedure and linear regression analysis involving a stepwise procedure were applied to select independent predictors.

Positive cores, PCR, CVR and PSAD were included in our assessing credibility model in the first stage. A significantly higher area under the receiver-operating curve was obtained in our model compared with CVR alone (0. 641 vs. 0. 517). In the second stage, patients with credibility of pre-operative Gleason score <0. 388 were subjected to further evaluation. Compared with the 2 statuses, the rate of overall concordance was significantly increased (60. 3 vs. 50. 2%, p = 0. 002).

We developed a follow-up strategy based on the new and correct system, which represents an important consideration procedure when clinicians make decisions with regard to treatment plans.

Urologia internationalis. 2016 Feb 05 [Epub ahead of print]

Jun Wang, Gong Cheng, Xiao Li, Yuan Huang, Yongsheng Pan, Chao Qin, Lixin Hua, Zengjun Wang

State Key Laboratory of Reproductive Medicine, Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.



Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.